Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VesiculoVax Trivalent Filovirus Vaccine
- Development stage
- Unknown
- Lead developer
- Aurobindo Pharma
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The VesiculoVax Trivalent Filovirus Vaccine is a recombinant viral vector vaccine candidate designed to provide broad protection against the three primary causes of filoviral hemorrhagic fever: Ebola virus (Zaire), Sudan virus, and Marburg virus. Developed using the VesiculoVax platform, originally by Profectus BioSciences and later advanced by the Sabin Vaccine Institute, the vaccine is a blend of three separate vectors. Each vector is a live-attenuated recombinant vesicular stomatitis virus (rVSV) engineered to express the surface glycoprotein (GP) of one of the target filoviruses. The platform incorporates specific safety modifications, including the translocation of the VSV N gene (N4) and the truncation of the G protein cytoplasmic tail (CT1), which significantly reduces neurovirulence while maintaining high immunogenicity. The vaccine works by inducing potent neutralizing antibodies and cellular immune responses against the viral glycoproteins, providing both rapid and durable protection, as demonstrated in non-human primate models.
- Brand names
- VesiculoVax
- Other names
- Trivalent Filovirus VaccinerVSV-N4CT1 Filovirus VaccinerVSV-N-4CT1 Filovirus VaccinerVSV-N 4CT1 Filovirus VaccinerVSV-GP Trivalent Vaccine
02
Targets
PYG (Glycogen phosphorylase)Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on VesiculoVax Trivalent Filovirus Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VesiculoVax Trivalent Filovirus Vaccine.